Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.08-6.5%$9.35$2.09▼$14.84$501.90M0.055.39 million shs2.20 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.34%+0.66%-16.63%-19.04%+37.14%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.6408 of 5 stars3.32.00.00.03.21.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00111.86% UpsideCurrent Analyst RatingsLatest ALT, ADR, and TTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,167.21N/AN/A$2.75 per share2.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)Latest ALT, ADR, and TTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.89 million67.99 millionOptionableALT, ADR, and TTB HeadlinesSourceHeadlineAltimmune (NASDAQ:ALT) Shares Down 5.3% marketbeat.com - April 24 at 6:15 PM3 Speculative Weight Loss Drug Stocks to Bet On for Big Gainsinvestorplace.com - April 24 at 6:33 AMAltimmune (NASDAQ:ALT) Shares Up 6.5%marketbeat.com - April 22 at 4:46 PMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?marketbeat.com - April 22 at 6:05 AMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (ALT)marketbeat.com - April 22 at 6:05 AMCoronavirus (COVID-19) Treatment Market Industry Share, Growth, Trends Analysis by 2032taiwannews.com.tw - April 19 at 11:30 PMGlobal COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023finance.yahoo.com - April 19 at 12:28 AMAltimmune, Inc. (ALT)finance.yahoo.com - April 18 at 6:22 AM5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffrabiospace.com - April 16 at 9:20 PMAltimmune (NASDAQ:ALT) Shares Down 7% marketbeat.com - April 15 at 5:31 PMBuy Altimmune's Potential Market Disruption With Pemvidutideseekingalpha.com - April 12 at 1:10 PM3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024investorplace.com - April 11 at 12:24 PMForget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.fool.com - April 9 at 6:45 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?marketbeat.com - April 9 at 6:08 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? marketbeat.com - April 9 at 6:07 AMAltimmune (NASDAQ:ALT) Shares Down 5.2% marketbeat.com - April 8 at 11:59 AMTimelo Investment Management Inc. Grows Stock Position in Altimmune, Inc. (NASDAQ:ALT)marketbeat.com - April 6 at 6:39 PMHC Wainwright Weighs in on Altimmune, Inc.'s Q1 2024 Earnings (NASDAQ:ALT)marketbeat.com - April 4 at 8:48 AMAltimmune (NASDAQ:ALT) Stock Price Down 8.1% After Analyst Downgrademarketbeat.com - April 2 at 10:27 AMThe 3 Best Biotech Stocks to Buy in April 2024investorplace.com - April 1 at 9:09 PMAltimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Ratingmarkets.businessinsider.com - April 1 at 8:08 PMAltimmune (NASDAQ:ALT) Price Target Lowered to $12.00 at HC Wainwrightmarketbeat.com - April 1 at 1:38 PMEli Lilly: Three Threats To Its Huge Rallyseekingalpha.com - March 31 at 4:34 PMA new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drugmsn.com - March 29 at 2:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityHigher Oil Prices Could Give NextEra’s Stock Earnings a BoostApril 24, 2024 10:40 AMView Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?4 Dividend Aristocrats Trading at a DiscountApril 1, 2024 6:10 AMView 4 Dividend Aristocrats Trading at a DiscountCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? All Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
